A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Idelalisib (Primary) ; Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 12 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 08 Jul 2014 Rituximab has been removed from the trial as reported by ClinicalTrials.gov record.
- 08 Jul 2014 Planned number of patients changed from 99 to 106 as reported by ClinicalTrials.gov record.